FDA Flags J&J For Inadequate Oversight Of Consumer Devices

FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, including K-Y moisturizers, after finding shortcomings in post-market monitoring and pre-market notification. The agency’s May 22 warning letter does not cite manufacturing issues.

More from Post-Marketing Regulation & Studies

More from Product Reviews